Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 5/20 | 0.54 |
| ▸ | MAOA | P21397 | 2/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | GRIA2 | P42262 | 14/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215911 | 1.00 | KDM1A (0.54) | KDM1AMAOAMAOBGRIA2KCNH2 | |
| SCHEMBL12514031 | 1.00 | KDM1A (0.54) | KDM1AMAOAMAOBGRIA2KCNH2 | |
| SCHEMBL2215179 | 0.83 | GRIA4 (0.57) | KDM1AMAOAMAOBGRIA2KCNH2 | |
| SCHEMBL2216216 | 0.83 | GRIA4 (0.57) | KDM1AMAOAMAOBGRIA2KCNH2 | |
| SCHEMBL12513941 | 0.78 | GRIA2 (0.50) | KDM1AGRIA2KCNH2 | |
| SCHEMBL2215518 | 0.77 | GRIA2 (0.56) | GRIA2KCNH2 | |
| SCHEMBL12513978 | 0.77 | GRIA2 (0.56) | GRIA2KCNH2 | |
| SCHEMBL2215515 | 0.77 | GRIA2 (0.56) | GRIA2KCNH2 | |
| SCHEMBL2211452 | 0.77 | GRIA2 (0.54) | KDM1AMAOAMAOBGRIA2KCNH2 | |
| SCHEMBL2211455 | 0.77 | GRIA2 (0.54) | KDM1AMAOAMAOBGRIA2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | claimed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | claimed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | claimed |
| EP-1848695-B1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LTD (GB) | 2011-07-27 | — | — | EP | disclosed |
| US-7790758-B2 | glutamate receptors agonists; especially to treat psychotic conditions, including schizophrenia and enhancement of cognition; N-{-2-[4-(6-fluoro-3-pyridinyl)phenyl]cyclopropyl}-2-propanesulfonamide; stereoselectively epoxidising a suitable styrene; coupling with boronic acid derivatives | GLAXO GROUP LIMITED (GB) | 2010-09-07 | — | — | US | disclosed |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GLAXO GROUP LIMITED (GB) | 2008-07-10 | — | — | US | disclosed |
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2008-06-12 | — | — | US | disclosed |
| EP-1848695-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2007-10-31 | — | — | EP | disclosed |
| WO-2006087169-A1 | COMPOUNDS WHICH POTENTIATE GLUTAMATE RECEPTOR AND USES THEREOF IN MEDICINE | GLAXO GROUP LIMITED (GB) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139472-A1 | UPREGULATING BDNF LEVELS TO MITIGATE MENTAL RETARDATION | BDNF, MECP2, NTRK2 | KDM1A 1854/4885MAOA 2566/4885MAOB 2822/4885 |
| US-20080167351-A1 | Compounds Which Potentiate Glutamate Receptor and Uses Thereof in Medicine | GRIN1, GRM2, GRM1 | KDM1A 3326/4885MAOA 2383/4885MAOB 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.